Drug Landscape ›
fluocinolone acetonide intravitreal implant ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 26
Most-reported reactions
Device Dislocation — 7 reports (26.92%) Corneal Oedema — 3 reports (11.54%) Condition Aggravated — 2 reports (7.69%) Device Breakage — 2 reports (7.69%) Device Malfunction — 2 reports (7.69%) Hypotony Of Eye — 2 reports (7.69%) Implant Site Fibrosis — 2 reports (7.69%) Implant Site Reaction — 2 reports (7.69%) Intraocular Pressure Increased — 2 reports (7.69%) Lymphoma — 2 reports (7.69%)
Source database →
fluocinolone acetonide intravitreal implant in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is fluocinolone acetonide intravitreal implant approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for fluocinolone acetonide intravitreal implant in United States?
Bausch & Lomb Incorporated is the originator. The local marketing authorisation holder may differ — check the official source linked above.